Articles
Preclinical data implicate the ELR+ chemokine/CXCR2 axes in the pathogenesis of CCA, warranting further studies to define its role in CCA. Read More ›
Preliminary results of a phase 2 study suggest that the addition of the PI3K inhibitor copanlisib to chemotherapy in the first-line setting was not associated with survival benefit in patients with advanced CCA. Read More ›
AKT and NOTCH intracellular domain (NICD) targets YAP and SOX9 might be potential targets for therapeutic intervention in intrahepatic CCA subsets, while cholestatic injury or NASH might induce hepatocyte-to-cholangiocyte reprogramming that increases risk of intrahepatic CCA. Read More ›
Interim analysis of the part 2 dose-expansion portion of an ongoing 2-part phase 1 Japanese study shows that the FGFR1 tyrosine kinase inhibitor E7090 was active with a manageable safety profile in CCA patients with FGFR2 gene fusion. Read More ›
Establishing protocols for side-effect reporting and management beforehand can maximize adherence to PARP inhibitor maintenance therapy. Read More ›
Although the combination of bevacizumab and olaparib showed superior progression-free survival compared with bevacizumab plus placebo as upfront maintenance therapy in women with advanced ovarian cancer, the lack of an olaparib monotherapy comparator limits meaningful interpretation. Read More ›
The rate of overall survival was similar between nivolumab and either gemcitabine or pegylated liposomal doxorubicin in the open-label, randomized phase 3 NINJA clinical trial of patients with platinum-resistant ovarian cancer, but the overall duration of response was longer in the nivolumab arm. Read More ›
In the FORWARD II clinical trial, mirvetuximab soravtansine combined with carboplatin and bevacizumab induced an overall response rate of 83% in patients with recurrent platinum-sensitive ovarian cancer. Read More ›
Copay maximizer programs are replacing copay accumulator programs, and the trend toward increasing cost burden for patients continues. Read More ›
Single cord blood transplantation could be an effective treatment option for AML patients aged ≥60 years, but the risks for engraftment failure and early nonrelapse mortality should be considered. Read More ›